Active Biotech Toekomstige groei

Future criteriumcontroles 2/6

Er wordt voorspeld dat Active Biotech de winst en omzet met respectievelijk 62.1% en 134.1% per jaar zal laten groeien.

Belangrijke informatie

62.1%

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	49.3%
Inkomstengroei	134.1%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	23 Oct 2024

Recente toekomstige groei-updates

Recent updates

Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Jun 05

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Nov 09

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

May 03

We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Jan 18

Winst- en omzetgroeiprognoses

OM:ACTI - Toekomstschattingen van analisten en financiële gegevens uit het verleden (SEK Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	28	-2	N/A	-2	1
12/31/2025	9	-27	N/A	-27	1
12/31/2024	N/A	-39	N/A	-41	1
9/30/2024	N/A	-42	-40	-40	N/A
6/30/2024	N/A	-44	-42	-42	N/A
3/31/2024	N/A	-45	-45	-45	N/A
12/31/2023	N/A	-46	-46	-46	N/A
9/30/2023	N/A	-48	-48	-48	N/A
6/30/2023	N/A	-51	-50	-50	N/A
3/31/2023	N/A	-54	-51	-51	N/A
12/31/2022	N/A	-58	-55	-55	N/A
9/30/2022	N/A	-60	-57	-57	N/A
6/30/2022	N/A	-57	-55	-55	N/A
3/31/2022	N/A	-56	-53	-53	N/A
12/31/2021	N/A	-50	-46	-46	N/A
9/30/2021	6	-38	-35	-35	N/A
6/30/2021	6	-35	-33	-33	N/A
3/31/2021	6	-32	-29	-29	N/A
12/31/2020	7	-32	-32	-32	N/A
9/30/2020	1	-39	-38	-38	N/A
6/30/2020	2	-40	-37	-37	N/A
3/31/2020	3	-36	-40	-40	N/A
12/31/2019	8	-34	-36	-36	N/A
9/30/2019	12	-32	-35	-35	N/A
6/30/2019	16	-31	-37	-37	N/A
3/31/2019	21	-35	-38	-38	N/A
12/31/2018	20	-37	-41	-41	N/A
9/30/2018	21	-88	-41	-41	N/A
6/30/2018	21	-88	N/A	-43	N/A
3/31/2018	20	-103	N/A	-44	N/A
12/31/2017	20	-109	N/A	-46	N/A
9/30/2017	22	-63	N/A	-52	N/A
6/30/2017	21	-67	N/A	-57	N/A
3/31/2017	20	-59	N/A	-61	N/A
12/31/2016	19	-60	N/A	-73	N/A
9/30/2016	17	-86	N/A	-86	N/A
6/30/2016	18	-97	N/A	-123	N/A
3/31/2016	17	-152	N/A	-187	N/A
12/31/2015	16	-194	N/A	-218	N/A
9/30/2015	14	-210	N/A	-245	N/A
6/30/2015	12	-243	N/A	-256	N/A
3/31/2015	11	-229	N/A	-243	N/A
12/31/2014	10	-232	N/A	-267	N/A
9/30/2014	12	-257	N/A	-157	N/A
6/30/2014	116	-171	N/A	-159	N/A
3/31/2014	116	-194	N/A	-170	N/A
12/31/2013	116	-212	N/A	-102	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ACTI de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ACTI de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ACTI de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van ACTI ( 134.1% per jaar) zal naar verwachting sneller groeien dan de markt Swedish ( 0.05% per jaar).

Hoge groei-inkomsten: De omzet van ACTI ( 134.1% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ACTI naar verwachting over 3 jaar hoog zal zijn

Active Biotech Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

No longer forecast to breakeven

No longer forecast to breakeven

Forecast breakeven date pushed back to 2025

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Price target decreased to kr2.50

Recent updates

New major risk - Financial position

New major risk - Market cap size

New minor risk - Share price stability

Active Biotech AB (Publ) Reports Intention Inaugural Interocular Concentrations Achieves in A Clinical Bylistribution Study of Laquinimod Eye Drops

No longer forecast to breakeven

Active Biotech Provides Update on the Clinical Phase Ib/IIa Study with Tasquinimod in Relapsed Refractory Multiple Myeloma

Active Biotech Enters Agreement for A Clinical Study of Tasquinimod in Myelofibrosis

Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Active Biotech AB (publ) Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops

Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

No longer forecast to breakeven

New major risk - Revenue and earnings growth

Active Biotech AB (publ), Annual General Meeting, May 22, 2024

New minor risk - Shareholder dilution

Active Biotech AB (Publ) Provides Update on the Scheduled Clinical Program for 2024

Active Biotech AB (Publ) Appoints Mats Arnhög and Petter Wingstrand to Nomination Committee

Forecast breakeven date pushed back to 2025

Active Biotech AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.135046 million.

Active Biotech AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 51.135046 million.

Forecast to breakeven in 2024

Active Biotech AB (publ) Enters into Clinical Trial Collaboration Agreement for a Clinical Study with Tasquinimod in Myelofibrosis

Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

New major risk - Share price stability

Insufficient new directors

Active Biotech Announces Positive Interim Data from an Ongoing Study with Tasquinimod in Relapsed and Refractory Multiple Myeloma

Active Biotech AB (Publ) Confirms Positive Clinical Safety Profile of Laquinimod Eye Drops

Active Biotech AB (publ) to Report First Half, 2023 Results on Aug 24, 2023

Active Biotech's Announces Nomination Committee

Forecast to breakeven in 2024

Active Biotech AB (publ) to Report Fiscal Year 2022 Results on Feb 09, 2023

Active Biotech AB (Publ) Announces Successful Completion of the First Stage of the Phase Iia Clinical Trial of Naptumomab in Combination with Docetaxel and the Study Is Now Enrolling into the Second Stage

Active Biotech AB (publ) announces that Food and Drug Administration has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis

Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

Price target decreased to kr2.50

High number of new and inexperienced directors

Active Biotech AB (publ) to Report Q3, 2022 Results on Nov 03, 2022

Active Biotech Announces First Patient Dosed in the Combination Part of the Phase Ib/IIa Study of Tasquinimod in Multiple Myeloma

Active Biotech AB (publ) Announces First Subject Dosed in Phase I Clinical Study with Eye-Drop Formulation of Laquinimod

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Active Biotech AB (publ) Provides Status Update of its Clinical Naptumomab Project

Independent Director recently bought kr60k worth of stock

Independent Chairman of the Board recently bought kr259k worth of stock

Independent Chairman of the Board recently bought kr259k worth of stock

Independent Chairman of the Board recently bought kr259k worth of stock

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Active Biotech Receive Milestone Payment from Neotx

New 90-day low: kr1.44

Active Biotech AB Appoints Elaine Sullivan as A Director

New 90-day low: kr1.50

New 90-day low: kr1.98

New 90-day low: kr2.15

New 90-day low - kr2.48

Earnings released

New 90-day high - kr2.88

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven